FDA Approves Tarceva For Pancreatic Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental NDA approval for Genentech/OSI’s erlotinib, previously approved for lung cancer, follows advisory committee recommendation.